Missing Script

Get updates

Evidence Explorer / MS-N203 / Supportive physical care / Appraised November 1, 2026

A small within-person randomized study found less acute radiation dermatitis under Hydrofilm polyurethane dressing than on the area treated with 5% urea lotion. It is a useful signal, but the split-breast design and small sample require cautious interpretation.

Evidence at a glance

  • Population: 62 people receiving breast radiotherapy after breast-conserving surgery.
  • Design: medial or lateral breast area randomized to Hydrofilm; the other area received 5% urea lotion.
  • Result: mean maximum dermatitis grade 0.35 under film vs 1.33 in the control area.
  • Other finding: no moist desquamation was reported under the film; itching and pain were lower.
  • Evidence label: promising small within-person randomized evidence.

What was studied

Each participant served as their own control, which reduces between-person differences in skin type and radiotherapy exposure. The investigators reported an 89.3% response rate favoring the film.

Within-person designs are efficient, but the two skin regions are not completely independent. Film visibility also prevents blinding, and local friction, folds and dose distribution can differ across a breast.

What this evidence cannot establish

The abstract does not report confidence intervals, full analyzed denominators for every outcome, clinically meaningful thresholds or long-term skin outcomes. These fields remain not verified.

This study does not establish that Hydrofilm is superior to every other barrier film, topical steroid or modern skin-care protocol.

Practical safety context

Adhesive dressings can cause itch, rash, blistering or skin stripping. Application and removal should follow the radiation department’s protocol, especially on fragile or already broken skin.

Seek assessment for spreading redness, fever, drainage, uncontrolled pain or a reaction extending beyond the treated field.

Questions for the care team

  • Is the film compatible with my radiation planning and daily setup?
  • Who will replace it and how will the skin be inspected?
  • What is the fallback plan if adhesive irritation develops?

Sources

Source note: The PubMed abstract and bibliographic record were checked; this is an abstract-level appraisal. Funding and conflict information is reported only where it was available in the checked source. No correction, retraction or expression of concern was identified in the PubMed-linked record on November 1, 2026.

This record is educational. It is not a personal treatment recommendation and does not replace advice from the oncology or radiation-care team. Symptom or toxicity outcomes do not demonstrate tumor response, recurrence prevention or longer survival.